Laboratory of Mycobacteriology

Print

email this

Tuberculosis (TB) remains a major global health problem, despite the widespread use of the Mycobacterium bovis bacillus Calmette-Guerin (BCG) vaccine and drug therapies.  Additionally, coinfection with Mycobacterium tuberculosis (MTB) and HIV (TB/HIV), as well as multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis, makes TB control even more difficult, complex and challenging.  The development of an efficacious and safe TB vaccine effective against MDR and XDR TB is critical for ultimately controlling these infections.

The Lee lab focuses its research in the following areas: development of safe and effective vaccines and immunotherapeutics for tuberculosis via novel strategies and approaches, evaluation of alternative methods to enhance the efficacy of current mycobacterial vaccines, development of recombinant mycobacterial vehicles capable of eliciting strong immune responses to HIV and other foreign antigens, and study of the virulence and immunogenicity of drug-resistant strains of MTB.